• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    New insider Adar1 Capital Management, Llc claimed ownership of 4,456,706 shares (SEC Form 3)

    4/11/25 8:58:32 PM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KROS alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    ADAR1 Capital Management, LLC

    (Last) (First) (Middle)
    3503 WILD CHERRY DRIVE
    BUILDING 9

    (Street)
    AUSTIN TX 78738

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    04/08/2025
    3. Issuer Name and Ticker or Trading Symbol
    Keros Therapeutics, Inc. [ KROS ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    Form filed by One Reporting Person
    X Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Common Stock 3,474,844 I By ADAR1 Partners, LP(1)(11)
    Common Stock 254,669 I By ADAR1 SPV I, LP(2)(11)
    Common Stock 727,193 I By Spearhead Insurance Solutions IDF, LLC(3)(11)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Put Option (obligation to buy) 02/27/2025 05/16/2025 Common Stock 30,000 $10 I By ADAR1 Partners, LP(4)(11)
    Put Option (obligation to buy) 04/03/2025 05/16/2025 Common Stock 83,600 $10 I By ADAR1 Partners, LP(5)(11)
    Put Option (obligation to buy) 04/03/2025 05/16/2025 Common Stock 17,800 $10 I By Spearhead Insurance Solutions IDF, LLC(6)(11)
    Put Option (right to sell) 10/01/2024 06/20/2025 Common Stock 1,400 $70 I By ADAR1 Partners, LP(7)(11)
    Put Option (right to sell) 10/02/2024 06/20/2025 Common Stock 100 $60 I By ADAR1 Partners, LP(8)(11)
    Put Option (right to sell) 10/01/2024 06/20/2025 Common Stock 200 $70 I By Spearhead Insurance Solutions IDF, LLC(9)(11)
    Cash-Settled Total Return Swaps (10) 02/02/2026 Common Stock 949,333 (10) I By ADAR1 Partners, LP(10)(11)
    1. Name and Address of Reporting Person*
    ADAR1 Capital Management, LLC

    (Last) (First) (Middle)
    3503 WILD CHERRY DRIVE
    BUILDING 9

    (Street)
    AUSTIN TX 78738

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    ADAR1 Partners, LP

    (Last) (First) (Middle)
    3503 WILD CHERRY DRIVE
    BUILDING 9

    (Street)
    AUSTIN TX 78738

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    ADAR1 Capital Management GP, LLC

    (Last) (First) (Middle)
    3503 WILD CHERRY DRIVE
    BUILDING 9

    (Street)
    AUSTIN TX 78738

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    Schneeberger Daniel

    (Last) (First) (Middle)
    3503 WILD CHERRY DRIVE
    BUILDING 9

    (Street)
    AUSTIN TX 78738

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    Explanation of Responses:
    1. ADAR1 Partners, LP is a direct beneficial owner 3,474,844 shares of Common Stock of the Issuer. As the investment manager of ADAR1 Partners, LP, ADAR1 Capital Management, LLC may be deemed to be an indirect beneficial owner of such shares. As the general partner of ADAR1 Partners, LP, ADAR1 Capital Management GP, LLC may be deemed to be the indirect beneficial owner of such shares. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Daniel Schneeberger may be deemed to be the indirect beneficial owner of such shares.
    2. ADAR1 SPV I, LP is a direct beneficial owner 254,669 shares of Common Stock of the Issuer. As the investment manager of ADAR1 SPV I, LP, ADAR1 Capital Management, LLC may be deemed to be an indirect beneficial owner of such shares. As the general partner of ADAR1 SPV I, LP, ADAR1 Capital Management GP, LLC may be deemed to be the indirect beneficial owner of such shares. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Daniel Schneeberger may be deemed to be the indirect beneficial owner of such shares.
    3. Spearhead Insurance Solutions IDF, LLC is a direct beneficial owner 727,193 shares of Common Stock of the Issuer. As the sub-advisor of Spearhead Insurance Solutions IDF, LLC, ADAR1 Capital Management, LLC may be deemed to be an indirect beneficial owner of such shares. As the manager of ADAR1 Capital Management, LLC, Daniel Schneeberger may be deemed to be the indirect beneficial owner of such shares.
    4. ADAR1 Partners, LP is party to put option contracts that provide for an obligation to buy 30,000 shares of Common Stock of the Issuer, if such put options are exercised by the counterparties to such put options. As the investment manager of ADAR1 Partners, LP, ADAR1 Capital Management, LLC may be deemed to be an indirect beneficial owner of such put options. As the general partner of ADAR1 Partners, LP, ADAR1 Capital Management GP, LLC may be deemed to be the indirect beneficial owner of such put options. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Daniel Schneeberger may be deemed to be the indirect beneficial owner of such put options.
    5. ADAR1 Partners, LP is party to put option contracts that provide for an obligation to buy 83,600 shares of Common Stock of the Issuer, if such put options are exercised by the counterparties to such put options. As the investment manager of ADAR1 Partners, LP, ADAR1 Capital Management, LLC may be deemed to be an indirect beneficial owner of such put options. As the general partner of ADAR1 Partners, LP, ADAR1 Capital Management GP, LLC may be deemed to be the indirect beneficial owner of such put options. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Daniel Schneeberger may be deemed to be the indirect beneficial owner of such put options.
    6. Spearhead Insurance Solutions IDF, LLC is party to put option contracts that provide for an obligation to buy 17,800 shares of Common Stock of the Issuer, if such put options are exercised by the counterparties to such put options. As the sub-advisor of Spearhead Insurance Solutions IDF, LLC, ADAR1 Capital Management, LLC may be deemed to be an indirect beneficial owner of such put options. As the manager of ADAR1 Capital Management, LLC, Daniel Schneeberger may be deemed to be the indirect beneficial owner of such put options.
    7. ADAR1 Partners, LP is a direct beneficial owner of fourteen put options, each with a right to sell 100 shares of Common Stock of the Issuer, exercisable by ADAR1 Partners, LP in its discretion. As the investment manager of ADAR1 Partners, LP, ADAR1 Capital Management, LLC may be deemed to be an indirect beneficial owner of such put options. As the general partner of ADAR1 Partners, LP, ADAR1 Capital Management GP, LLC may be deemed to be the indirect beneficial owner of such put options. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Daniel Schneeberger may be deemed to be the indirect beneficial owner of such put options.
    8. ADAR1 Partners, LP is a direct beneficial owner of one put option, with a right to sell 100 shares of Common Stock of the Issuer, exercisable by ADAR1 Partners, LP in its discretion. As the investment manager of ADAR1 Partners, LP, ADAR1 Capital Management, LLC may be deemed to be an indirect beneficial owner of such put option. As the general partner of ADAR1 Partners, LP, ADAR1 Capital Management GP, LLC may be deemed to be the indirect beneficial owner of such put option. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Daniel Schneeberger may be deemed to be the indirect beneficial owner of such put option.
    9. Spearhead Insurance Solutions IDF, LLC is a direct beneficial owner of two put options, each with a right to sell 100 shares of Common Stock of the Issuer, exercisable by Spearhead Insurance Solutions IDF, LLC in its discretion. As the sub-advisor of Spearhead Insurance Solutions IDF, LLC, ADAR1 Capital Management, LLC may be deemed to be an indirect beneficial owner of such put options. As the manager of ADAR1 Capital Management, LLC, Daniel Schneeberger may be deemed to be the indirect beneficial owner of such put option.
    10. ADAR1 Partners, LP previously entered into certain cash-settled total return swap agreements with an unaffiliated third-party financial institution, which as of the close of business on April 8, 2025, provide ADAR1 Partners, LP with economic exposure to an aggregate of 949,333 notional shares of Common Stock of the Issuer. The swap agreements provide the ADAR1 Partners, LP with economic results that are comparable to the economic results of ownership but do not provide ADAR1 Partners, LP with the power to vote or direct the voting or dispose of or direct the disposition of the shares of common stock that are the subject of the swap agreements (the "Subject Shares"). Each of the Reporting Persons disclaims beneficial ownership of the Subject Shares except to the extent of its or his pecuniary interest therein.
    11. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
    ADAR1 Capital Management, LLC, By /s/ Daniel Schneeberger, Manager 04/11/2025
    ADAR1 Partners, LP, By /s/ Daniel Schneeberger, Manager 04/11/2025
    ADAR1 Capital Management GP, LLC, By /s/ Daniel Schneeberger, Manager 04/11/2025
    /s/ Daniel Schneeberger 04/11/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $KROS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KROS

    DatePrice TargetRatingAnalyst
    10/20/2025$26.00Overweight
    Wells Fargo
    6/10/2025$18.00Buy → Neutral
    BofA Securities
    1/21/2025Overweight → Neutral
    Cantor Fitzgerald
    1/17/2025$15.00Outperform → Neutral
    Wedbush
    12/16/2024$102.00 → $63.00Outperform
    Oppenheimer
    12/16/2024Buy → Neutral
    Guggenheim
    12/13/2024$100.00 → $47.00Buy
    H.C. Wainwright
    12/12/2024Buy → Hold
    TD Cowen
    More analyst ratings

    $KROS
    SEC Filings

    View All

    SEC Form 144 filed by Keros Therapeutics Inc.

    144 - Keros Therapeutics, Inc. (0001664710) (Subject)

    3/31/26 9:57:38 PM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Keros Therapeutics Inc.

    SCHEDULE 13G/A - Keros Therapeutics, Inc. (0001664710) (Subject)

    3/27/26 10:16:30 AM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Keros Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Keros Therapeutics, Inc. (0001664710) (Filer)

    3/9/26 8:01:35 AM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KROS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wells Fargo initiated coverage on Keros Therapeutics with a new price target

    Wells Fargo initiated coverage of Keros Therapeutics with a rating of Overweight and set a new price target of $26.00

    10/20/25 8:00:48 AM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Keros Therapeutics downgraded by BofA Securities with a new price target

    BofA Securities downgraded Keros Therapeutics from Buy to Neutral and set a new price target of $18.00

    6/10/25 7:53:18 AM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Keros Therapeutics downgraded by Cantor Fitzgerald

    Cantor Fitzgerald downgraded Keros Therapeutics from Overweight to Neutral

    1/21/25 7:51:46 AM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KROS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Adar1 Capital Management, Llc bought $328,127 worth of shares (34,925 units at $9.40) (SEC Form 4)

    4 - Keros Therapeutics, Inc. (0001664710) (Issuer)

    4/11/25 9:57:19 PM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KROS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Seehra Jasbir

    4 - Keros Therapeutics, Inc. (0001664710) (Issuer)

    4/6/26 4:15:08 PM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form 4 filed by Cho Esther

    4/A - Keros Therapeutics, Inc. (0001664710) (Issuer)

    3/27/26 4:15:14 PM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Keros Therapeutics Inc.

    4 - Keros Therapeutics, Inc. (0001664710) (Issuer)

    3/11/26 4:39:18 PM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KROS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Keros Therapeutics Announces Collaboration with Sean M. Healey & AMG Center for ALS

    LEXINGTON, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced that it has entered into an agreement with the Massachusetts General Hospital ("MGH") for the design of a Phase 2 clinical trial evaluating rinvatercept in patients with amyotrophic lateral sclerosis ("ALS") within the Healey ALS MyMatch program ("ALS MyMatch"), led by the Sean M. Healey & AMG Ce

    3/9/26 8:00:00 AM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Keros Therapeutics Presents Additional Clinical Data from Its Rinvatercept Program at the 2026 MDA Clinical & Scientific Conference

    LEXINGTON, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced that it presented additional data from its Phase 1 clinical trial of rinvatercept (KER-065) in healthy volunteers at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference. "We are pleased to present additional data that further underscore the wide-ranging therapeutic potential

    3/9/26 8:00:00 AM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results

    LEXINGTON, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2025. "The previous year was an important period of transition for the Company, during which we sharpened our strategic priorities," said Jasbir S. Seehra, Ph.D., President and Chief Executive

    3/4/26 4:01:00 PM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KROS
    Leadership Updates

    Live Leadership Updates

    View All

    Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results

    LEXINGTON, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2025. "The previous year was an important period of transition for the Company, during which we sharpened our strategic priorities," said Jasbir S. Seehra, Ph.D., President and Chief Executive

    3/4/26 4:01:00 PM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Keros Therapeutics Appoints Charles Newton to its Board of Directors

    LEXINGTON, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced the appointment of Charles Newton to its Board of Directors, effective March 9, 2026. "We are pleased to welcome Mr. Newton to Keros' Board of Directors," said Jean-Jacques Bienaimé, Chair of the Board of Directors. "His extensive expertise in healthcare finance and capital markets, coupled with

    2/26/26 4:01:00 PM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Keros Therapeutics Appoints Yung H. Chyung, M.D., as Chief Medical Officer

    LEXINGTON, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced the appointment of Yung H. Chyung, M.D., as Keros' Chief Medical Officer, effective as of November 1, 2024. "We are thrilled to welcome Yung to Keros and look forward to leveraging his development and TGF-ß superfamily expertise as we continue to advance our clinical programs," said Chair and Chi

    10/16/24 8:00:00 AM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KROS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Keros Therapeutics Inc. (Amendment)

    SC 13G/A - Keros Therapeutics, Inc. (0001664710) (Subject)

    2/13/24 6:38:35 PM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Keros Therapeutics Inc. (Amendment)

    SC 13G/A - Keros Therapeutics, Inc. (0001664710) (Subject)

    2/9/24 9:16:07 AM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Keros Therapeutics Inc. (Amendment)

    SC 13G/A - Keros Therapeutics, Inc. (0001664710) (Subject)

    1/26/24 5:26:51 PM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KROS
    Financials

    Live finance-specific insights

    View All

    Keros Therapeutics Reports Third Quarter 2025 Financial Results

    LEXINGTON, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today reported financial results for the quarter ended September 30, 2025. "We are excited that our partner Takeda plans to advance elritercept into a Phase 3 clinical trial to evaluate elritercept in the first-line setting in myelodysplastic syndromes," said Jasbir S. Seehra, Ph.D., President and Chief Executiv

    11/5/25 4:01:00 PM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ADAR1 Sends Open Letter to Keros Board of Directors Urging the Board to Engage Constructively on Strategy, Capital Allocation and Board Refreshment

    AUSTIN, Texas, Aug. 21, 2025 /PRNewswire/ -- ADAR1 Capital Management, LLC (together with its affiliates, "ADAR1" or "we"), the largest stockholder of Keros Therapeutics (NASDAQ:KROS) ("Keros" or the "Company") with approximately 13.3% of the Company's outstanding shares, today released an open letter to Keros' Board of Directors (the "Board") expressing its disappointment with the Board's refusal to engage with ADAR1 on the Company's strategy, capital allocation priorities and Board refreshment. The full text of the letter is below. Dear Members of the Board: In July, we wrote to the Board privately to propose an in-person meeting to discuss our ideas to maximize stockholder value. We had

    8/21/25 8:30:00 AM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Keros to Exclusively Prioritize the Clinical Advancement of KER-065

    Company Discontinuing Development of Cibotercept (KER-012) Announces Board and Leadership Changes Designed to Support Streamlined Operational Structure and Strategic Realignment LEXINGTON, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced a strategic realignment designed to reallocate resources towards the development of its key clinical program, KER-065. As part of thi

    8/6/25 4:15:00 PM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care